CD19 and acute lymphoblastic leukemia: In the landmark phase II ELIANA trial of 75 pediatric and young adult patients with R/R ALL receiving tisagenlecleucel (anti-CD19 CAR construct), 81% of patients achieved complete remission (CR), all with no minimal residual disease at 3 months.